ロード中...
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase
PURPOSE: Gemcitabine (GEM) is currently the standard first line treatment for pancreatic cancer; however, the overall survival of patients with this disease remains poor. Imexon is a pro-oxidant small molecule which produced a high response rate in combination with GEM in a phase I trial in pancreat...
保存先:
| 主要な著者: | , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2010
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2987536/ https://ncbi.nlm.nih.gov/pubmed/20339847 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1306-0 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|